Vascular Disease
Sanger Heart & Vascular Institute offers access to the latest clinical trials and investigational devices as part of our commitment to delivering the highest quality vascular care.
Recent Highlights
In 2022, we implemented ERAS®, with the goal of improving outcomes while continuing to reduce complications and length of stay for patients undergoing lower extremity revascularization procedures.
Pioneering the Use of Implantable Fish Skin
Kerecis Omega3 SurgiBind implantable fish skin recruits human cells when it is grafted and is gradually converted into living tissue. Sanger is using this innovative approach to help accelerate wound healing in patients with non-healing or slow-healing wounds. Kerecis has designated Sanger a Center of Excellence for this work.
Research and Clinical Trials
Transcarotid stenting has been shown to have excellent outcomes in multiple recent studies. It was recently approved by the FDA for use in normal risk patients. After leading the way and being one of the top enrollers in the ROADSTER 2 trial, Sanger is now part of the ROADSTER 3 trial.
Sanger was one of the highest enrollers in the Percutaneous Deep Vein Arterialization for the Treatment of Late Stage Chronic Limb Threatening Ischemia (PROMISE) II trial and we were selected to be part of the PROMISE III trial.
New Cath Lab
A new, state-of-the-art vascular catheterization lab has opened at Atrium Health Carolinas Medical Center.
-
1st in the world to commercially use the Kerecis Omega3 SurgiBind implantable fish skin graft.
Transcarotid Artery Revascularization
-
85
TCAR Elective Procedures
2022
M2S, September 2021 - August 2022 -
393
TCAR Total Procedures
Since Program Inception
M2S, January 2018 - August 2022 -
0.0%
TCAR Elective Procedures
Stroke Complication Rate
M2S, September 2021 - August 2022
Lower Extremities
-
762
Percutaneous Intervention Procedures
2022
M2S, September 2021 - August 2022 -
3,979
Percutaneous Intervention Procedures
Since Program Inception
M2S, January 2011 - August 2022 -
0.79%
Percutaneous Interventions
In-Hospital Mortality Rate
M2S, September 2021 - August 2022 -
1,222
Revascularization Bypass (infra-inguinal) Procedures
Since Program Inception
M2S, January 2011 - August 2022
Carotid Endarterectomy
-
164
Elective Procedures
2022
M2S, September 2021 - August 2022 -
1,733
Elective Procedures
Since Program Inception
M2S, January 2011 - August 2022 -
0.0%
Elective Procedures
Stroke Complication Rate
M2S, September 2021 - August 2022 -
0.0%
Elective Procedures
In-hospital Mortality Rate
M2S, September 2021 - August 2022
Publications and Presentations
Pivotal Study Evaluating the Safety and Effectiveness of the Abre Venous Self-Expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction. Murphy M, Gibson K, Sapoval M, Dexter DJ, Kolluri R, Razavi M, Black S. Circ Cardiovasc Interv. 2022 Feb; 15(2):e010960. PMID: 35105153.
Treating Calcified PAD With the New Shockwave M5+ IVL Catheter. Yammine H. Vascular Disease Management. 2022 July.
TCAR: A Provider’s Eye View on a Patient’s Experience. Briggs C. Silk Road website. 2022 Aug.
Transcarotid Artery Revascularization (TCAR) in the Frail. Yammine H, Briggs C, Arko FR III. Ann Vasc Surg. 2022 Aug; 84:135-136. Doi: 10.1016/j.avsg.2022.02.002. Epub 2022 Mar 5. PMID: 35257912.
Utilization of Coronary Computed Tomography Angiography and Computed Tomography-derived Fractional Flow Reserve to Reduce Cardiovascular Death in a Critical Limb Ischemia Cohort. J Stanley G, Hajostek M, Briggs C, Yammine H, Cresposoto H, Nussbaum T, Arko FR. Vasc Surg. Volume 75, Issue1, e32-33. 2022 Jan 1.